Calvo-Pinilla E - Search Results

1

Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor.

Calvo-Pinilla E, Rodríguez-Calvo T, Anguita J, Sevilla N, Ortego J. Calvo-Pinilla E, et al. PLoS One. 2009;4(4):e5171. doi: 10.1371/journal.pone.0005171. Epub 2009 Apr 9. PLoS One. 2009. PMID: 19357779 Free PMC article.

2

Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection.

Calvo-Pinilla E, Rodríguez-Calvo T, Sevilla N, Ortego J. Calvo-Pinilla E, et al. Vaccine. 2009 Dec 11;28(2):437-45. doi: 10.1016/j.vaccine.2009.10.027. Epub 2009 Oct 24. Vaccine. 2009. PMID: 19857449

3

Experimental oral infection of bluetongue virus serotype 8 in type I interferon receptor-deficient mice.

Calvo-Pinilla E, Nieto JM, Ortego J. Calvo-Pinilla E, et al. J Gen Virol. 2010 Nov;91(Pt 11):2821-5. doi: 10.1099/vir.0.024117-0. Epub 2010 Aug 18. J Gen Virol. 2010. PMID: 20719994

4

A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.

Castillo-Olivares J, Calvo-Pinilla E, Casanova I, Bachanek-Bankowska K, Chiam R, Maan S, Nieto JM, Ortego J, Mertens PP. Castillo-Olivares J, et al. PLoS One. 2011 Jan 26;6(1):e16503. doi: 10.1371/journal.pone.0016503. PLoS One. 2011. PMID: 21298069 Free PMC article.

5

Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen.

Franceschi V, Capocefalo A, Calvo-Pinilla E, Redaelli M, Mucignat-Caretta C, Mertens P, Ortego J, Donofrio G. Franceschi V, et al. Vaccine. 2011 Apr 5;29(16):3074-82. doi: 10.1016/j.vaccine.2011.01.075. Epub 2011 Feb 12. Vaccine. 2011. PMID: 21320537

6

Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus.

Calvo-Pinilla E, Navasa N, Anguita J, Ortego J. Calvo-Pinilla E, et al. PLoS One. 2012;7(4):e34735. doi: 10.1371/journal.pone.0034735. Epub 2012 Apr 13. PLoS One. 2012. PMID: 22514660 Free PMC article.

7

Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.

Jabbar TK, Calvo-Pinilla E, Mateos F, Gubbins S, Bin-Tarif A, Bachanek-Bankowska K, Alpar O, Ortego J, Takamatsu HH, Mertens PP, Castillo-Olivares J. Jabbar TK, et al. PLoS One. 2013 Apr 12;8(4):e60574. doi: 10.1371/journal.pone.0060574. Print 2013. PLoS One. 2013. PMID: 23593251 Free PMC article.

8

Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus.

de la Poza F, Calvo-Pinilla E, López-Gil E, Marín-López A, Mateos F, Castillo-Olivares J, Lorenzo G, Ortego J. de la Poza F, et al. PLoS One. 2013 Jul 23;8(7):e70197. doi: 10.1371/journal.pone.0070197. Print 2013. PLoS One. 2013. PMID: 23894615 Free PMC article.

9

Recombinant vaccines against bluetongue virus.

Calvo-Pinilla E, Castillo-Olivares J, Jabbar T, Ortego J, de la Poza F, Marín-López A. Calvo-Pinilla E, et al. Virus Res. 2014 Mar;182:78-86. doi: 10.1016/j.virusres.2013.11.013. Epub 2013 Nov 25. Virus Res. 2014. PMID: 24287057 Review.

10

Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation.

Calvo-Pinilla E, de la Poza F, Gubbins S, Mertens PP, Ortego J, Castillo-Olivares J. Calvo-Pinilla E, et al. Virus Res. 2014 Feb 13;180:23-30. doi: 10.1016/j.virusres.2013.12.002. Epub 2013 Dec 12. Virus Res. 2014. PMID: 24333835

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results